Paul Tudor Jones II: 24 Ultragenyx Pharmaceutical transactions (Tudor

24 Paul Tudor Jones II Ultragenyx Pharmaceutical Trades

Paul Tudor Jones II's position in Ultragenyx Pharmaceutical is currently worth $897 Thousand. That's 0.01% of their equity portfolio (1000th largest holding). The first Ultragenyx Pharmaceutical trade was made in Q3 2015. Since then Paul Tudor Jones II bought shares thirteen more times and sold shares on ten occasions. The investor's estimated purchase price is $935 Thousand, resulting in a loss of 4.1%.

Avg closing price

Price range

New holding (+22.5 Thousand shares) Q1 2025

Avg closing price $41.62

Price range $36.21 - $45.78

Sold -54.5 Thousand shares Q4 2024

Avg closing price $49.41

Price range $42.07 - $57.70

Increased shares by 57.7% (+19.9 Thousand shares) Q3 2024

Avg closing price $50.87

Price range $40.21 - $59.36

New holding (+34.6 Thousand shares) Q2 2024

Avg closing price $42.70

Price range $37.42 - $51.61

Sold -36.9 Thousand shares Q3 2023

Avg closing price $39.62

Price range $34.92 - $46.66

Sold 1.5% shares (-548 shares) Q2 2023

Avg closing price $46.38

Price range $37.35 - $52.15

New holding (+37.5 Thousand shares) Q1 2023

Avg closing price $42.91

Price range $36.99 - $48.71

Sold -35.7 Thousand shares Q4 2022

Avg closing price $39.33

Price range $33.72 - $46.33

Increased shares by 118.0% (+19.3 Thousand shares) Q3 2022

Avg closing price $51.39

Price range $39.96 - $66.14

New holding (+16.4 Thousand shares) Q2 2022

Avg closing price $61.54

Price range $45.80 - $85.40

Sold -4.43 Thousand shares Q1 2022

Avg closing price $69.58

Price range $62.20 - $84.40

Sold 87.6% shares (-31.4 Thousand shares) Q4 2021

Avg closing price $81.37

Price range $73.71 - $87.86

Increased shares by 125.7% (+19.9 Thousand shares) Q3 2021

Avg closing price $90.39

Price range $77.92 - $102.40

New holding (+15.9 Thousand shares) Q2 2021

Avg closing price $104.18

Price range $92.19 - $115.71

Sold -17.7 Thousand shares Q1 2021

Avg closing price $136.14

Price range $106.90 - $167.73

Increased shares by 10.8% (+1.73 Thousand shares) Q4 2020

Avg closing price $118.63

Price range $84.40 - $177.39

Increased shares by 49.9% (+5.32 Thousand shares) Q3 2020

Avg closing price $82.89

Price range $72.98 - $90.00

New holding (+10.7 Thousand shares) Q2 2020

Avg closing price $66.19

Price range $46.91 - $78.22

Sold -14.2 Thousand shares Q4 2019

Avg closing price $41.26

Price range $36.08 - $45.83

New holding (+14.2 Thousand shares) Q3 2019

Avg closing price $54.32

Price range $42.50 - $63.11

News about Ultragenyx Pharmaceutical Inc. and Paul Tudor Jones II

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans

Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is sched...

zacks.com, 12 months ago

Ultragenyx Posts New Data From Bone Disease Study

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of ...

Benzinga, about 1 year ago

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval

globenewswire.com, about 1 year ago